Publications
Detailed Information
A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Hyun Sun | - |
dc.contributor.author | Youn, Jai Il | - |
dc.date.accessioned | 2009-11-26T03:04:43Z | - |
dc.date.available | 2009-11-26T03:04:43Z | - |
dc.date.issued | 2007-09-14 | - |
dc.identifier.citation | J Dermatolog Treat. 2007;18(5):286-90. | en |
dc.identifier.issn | 0954-6634 (Print) | - |
dc.identifier.uri | http://www.informaworld.com/smpp/content~db=all?content=10.1080/09546630701418747 | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17852632 | - |
dc.identifier.uri | https://hdl.handle.net/10371/15727 | - |
dc.description.abstract | BACKGROUND: Few reports have been issued which compare the efficacy and tolerability of cyclosporine dose adjustments before 12 weeks of treatment. OBJECTIVE: To compare the efficacy and tolerability of two different dosage regimens of cyclosporine in severe psoriasis. METHODS: This 12-week, prospective, open-label study included 61 severe psoriasis patients. Patients were assigned to a 2.5 mg/kg per day starting dose and an increasing regimen ('standard regimen') or a 5.0 mg/kg per day starting dose and a decreasing regimen ('step-down regimen') group. The end point included 50% and 75% reductions in Psoriasis Area and Severity Index (PASI) scores. Adverse events were also evaluated. RESULTS: According to a 50% PASI reduction (PASI 50), the response rate at 12 weeks was similar for two groups. The percentage of patients achieving a 75% PASI reduction (PASI 75) at 12 weeks was higher in the step-down regimen group. The mean time to PASI 50 or PASI 75 was shorter in the step-down regimen group. No difference was found between the two groups in terms of the number of patients with adverse events requiring intervention. CONCLUSION: This study suggests that the 'step-down' cyclosporine regimen offers an effective and safe therapeutic option for the management of severe psoriasis. | en |
dc.language.iso | en | - |
dc.publisher | Taylor & Francis | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Cyclosporine/*administration & dosage/adverse effects | en |
dc.subject | Drug Administration Schedule | en |
dc.subject | Drug Dosage Calculations | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Immunosuppressive Agents/*administration & dosage/adverse effects | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Psoriasis/*drug therapy/pathology | en |
dc.subject | Severity of Illness Index | en |
dc.subject | Skin/pathology | en |
dc.subject | Treatment Outcome | en |
dc.title | A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 윤현선 | - |
dc.contributor.AlternativeAuthor | 윤재일 | - |
dc.identifier.doi | 10.1080/09546630701418747 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.